Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles

Awotwe-Otoo, 2012, Application of quality by design elements for the development and optimization of an analytical method for protamine sulfate, J. Pharmaceut. Biomed., 62, 61, 10.1016/j.jpba.2012.01.002 Bozkir, 2005, Formulation and investigation of 5-FU nanoparticles with factorial design-based studies, II Farmaco., 60, 840, 10.1016/j.farmac.2005.06.016 Cagigal, 2001, PKa determination of angiotensin II receptor antagonists (ARA II) by spectroscopy, J. Pharmaceut. Biomed., 26, 477, 10.1016/S0731-7085(01)00413-7 Dolan, J. A guide to HPLC and LC-MS buffer selection. ACE HPLC Columns – ultra inert base-deactivated HPLC columns. 1–20. <www.ace-hplc.com> (accessed on 30.10.14). Gonzalez, 2009, Optimization and validation of a SPE-HPLC-PDA-fluorescence method for the simultaneous determination of drug used in combined cardiovascular therapy in human plasma, J. Pharmaceut. Biomed., 50, 630, 10.1016/j.jpba.2008.10.037 Grumbach, 2004, Hydrophilic interaction chromatography using silica columns for the retention of polar analytes and enhanced ESI-MS sensitivity, LC GC N. Am., 22, 1010 Grundy, 2004, Definition of metabolic syndrome – report of the national heart, lung and blood institute/American heart association conference on scientific issues related to definition. NHLBI/AHA conference proceedings, Circulation, 109, 433, 10.1161/01.CIR.0000111245.75752.C6 ICH Harmonized Tripartite Guideline, Validation of analytical procedures: Text and Methodology Q2 (R1), International Conference on Harmonization. Geneva, Switzerland, November 2005. <http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q2_R1/Step4/Q2_R1__Guideline.pdf> (accessed on 20.12.14). Kearney, 2005, Golden burden of hypertension: analysis of worldwide data, Lancet, 365, 217, 10.1016/S0140-6736(05)70151-3 Nagarwal, 2009, In situ forming formulation: development, evaluation and optimization using factorial design, AAPS PharmSciTech., 10, 977, 10.1208/s12249-009-9285-3 Rajput, 2011, Development and validation of a rapid RP-UPLC method for the determination of aspirin and dipyridamole in combined capsule formulation, Int. J. Pharm. Pharmaceut. Sci., 3, 156 Sagirli, 2007, Simultaneous HPLC analysis of olmesartan and hydrochlorothiazide in combined tablets and in vitro dissolution studies, Chromatographia, 66, 213, 10.1365/s10337-007-0304-9 Singh, 1995, Optimization and characterization of controlled release pellets coated with an experimental latex-I: anionic drug, Int. J. Pharm., 125, 243, 10.1016/0378-5173(95)00135-6 Singh, 2008, Optimization studies on design and evaluation of orodispersible formulation of indomethacin, AAPS PharmSciTech., 9, 60, 10.1208/s12249-007-9018-4 Solanki, 2014, Central composite design for validation of HPTLC method for simultaneous estimation of olmesartan medoxomil, amlodipine besylate and hydrochlorothiazide in tablets, Indian J. Pharm. Sci., 76, 179 Yahiaoui, 2010, Experimental design for copper cementation process in fixed bed reactor using two-level factorial design, Arabian J. Chem., 3, 187, 10.1016/j.arabjc.2010.04.009 Yang, 2010, Rapid resolution RP-HPLC-DAD method for simultaneous determination of sildenafil, vardenafil and tadalafil in pharmaceutical preparations and counterfeit drugs, Anal. Lett., 43, 373, 10.1080/00032710903402283 Ye, 2000, Design of experiment and data analysis by JMP® (SAS institute) in analytical method validation, J. Pharmaceut. Biomed., 23, 581, 10.1016/S0731-7085(00)00335-6